Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 2
2007 1
2008 3
2009 1
2010 4
2011 8
2012 7
2013 6
2014 7
2015 10
2016 14
2017 19
2018 15
2019 16
2020 22
2021 16
2022 26
2023 18
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

186 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 months (maximum, 85 months). ...CONCLUSIONS: In patients with gout and major cardiovascular coexisting conditions, febuxostat was nonin …
RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 mo …
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Gao L, Wang B, Pan Y, Lu Y, Cheng R. Gao L, et al. Clin Cardiol. 2021 Jul;44(7):907-916. doi: 10.1002/clc.23643. Epub 2021 May 20. Clin Cardiol. 2021. PMID: 34013998 Free PMC article. Review.
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This meta-analysis adds new evidence regarding the cardiovascular safety of febuxostat in patients. Initiation of febuxostat in patients was not as …
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This meta-analysis ad …
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Free article. Clinical Trial.
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safe …
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the ca …
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Becker MA, et al. N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373. N Engl J Med. 2005. PMID: 16339094 Free article. Clinical Trial.
The median reduction in tophus area was 83 percent in patients receiving 80 mg of febuxostat and 66 percent in those receiving 120 mg of febuxostat, as compared with 50 percent in those receiving allopurinol (P=0.08 for 80 mg of febuxostat vs. allopurinol; P= …
The median reduction in tophus area was 83 percent in patients receiving 80 mg of febuxostat and 66 percent in those receiving 120 mg …
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
RESULTS: Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. ...The incidence of gouty arthritis was significantly lower (P=0.007) in the febuxostat group (0.91%) than in the placeb …
RESULTS: Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in t …
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kohagura K, et al. Hypertens Res. 2023 Jun;46(6):1417-1422. doi: 10.1038/s41440-023-01198-x. Epub 2023 Feb 7. Hypertens Res. 2023. PMID: 36750608 Clinical Trial.
The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24-0.82; P = 0.0098). ...In patients with asymptomatic hyperuricemia without gout, febuxostat reduces the risk of development or worsen …
The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24 …
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N. Schumacher HR Jr, et al. Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209. Arthritis Rheum. 2008. PMID: 18975369 Free article. Clinical Trial.
OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects with hyperuricemia and gout, including persons with impaired renal function. ...Proportions of subjects experiencing any adverse event or serio …
OBJECTIVE: To compare the urate-lowering efficacy and safety of febuxostat, allopurinol, and placebo in a large group of subjects wit …
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Saag KG, Becker MA, White WB, Whelton A, Borer JS, Gorelick PB, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Saag KG, et al. Arthritis Rheumatol. 2022 Sep;74(9):1593-1601. doi: 10.1002/art.42160. Epub 2022 Aug 5. Arthritis Rheumatol. 2022. PMID: 35536764 Free PMC article. Clinical Trial.
OBJECTIVE: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Al …
OBJECTIVE: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) …
Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials.
Yang XH, Zhang BL, Cheng Y, Fu SK, Jin HM. Yang XH, et al. Ann Med. 2024 Dec;56(1):2332956. doi: 10.1080/07853890.2024.2332956. Epub 2024 May 13. Ann Med. 2024. PMID: 38738384 Free PMC article. Review.
PURPOSE: It is unknown whether febuxostat can delay the progression of kidney dysfunction and reduce kidney endpoint events. ...CONCLUSION: Febuxostat use is associated with a reduced risk of kidney events and a slow decline in eGFR. ...
PURPOSE: It is unknown whether febuxostat can delay the progression of kidney dysfunction and reduce kidney endpoint events. ...CONCL …
Febuxostat for treating chronic gout.
Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME. Tayar JH, et al. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD008653. doi: 10.1002/14651858.CD008653.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152264 Free PMC article. Review.
No other differences were observed.When comparing allopurinol to febuxostat at 24 to 52 weeks, the number of gout flares was not significantly different between the two groups, except for febuxostat 240 mg (RR 2.3; 95% CI 1.7 to 3.0). Patients on febuxostat 4 …
No other differences were observed.When comparing allopurinol to febuxostat at 24 to 52 weeks, the number of gout flares was not sign …
186 results